contraindications: Contraindicated in individuals with androgen-sensitive malignancy (prostate or breast carcinoma), severe hepatic impairment, untreated polycythaemia, or hypersensitivity to any oil-based injectable excipient. Concurrent use with anticoagulants (e.g. warfarin) requires INR monitoring as androgens potentiate anticoagulant effect.
side_effects: Aromatisation to oestradiol can cause gynaecomastia, water retention, and blood pressure elevation — risk is amplified in multi-compound stacks where total aromatase substrate from all agents accumulates. Androgenic effects include acne, accelerated scalp hair recession in genetically susceptible individuals, and virilisation in female users. Haematocrit elevation is cumulative across stack duration and should be tracked via full blood count.
monitoring: Obtain baseline and mid-cycle bloodwork panels covering: serum testosterone (total and free), oestradiol (E2 by LC-MS/MS for accuracy), haematocrit, haemoglobin, LDL-C, HDL-C, and PSA. When stacking with additional androgenic agents, add liver enzyme panels (ALT, AST) if any orals are included. Injection site inspection at each administration is mandatory — unusual warmth, swelling, or induration warrants immediate medical review.
pct: Post-cycle therapy with a SERM (tamoxifen 20mg/day or clomiphene 50mg/day for 4 weeks) can begin 3–5 days after the final Testo Rapid ampoule when all stack partners share comparable ester clearance windows. If a longer-ester compound was part of the stack, delay PCT entry until that compound's plasma levels have declined to sub-suppressive range, confirmed by bloodwork where feasible.